IFRX vs ARGX vs OMAB vs RARE vs IMVT

For growth investors, argenx SE (ARGX) is the stronger pick with 90.

1% revenue growth year-over-year, versus -83. 0% for InflaRx N. V. (IFRX). Grupo Aeroportuario del Centro Norte, S. A. B. de C. V. (OMAB) offers the better valuation at 16. 7x trailing P/E (0. 8x forward), making it the more compelling value choice. Analysts rate InflaRx N. V. (IFRX) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Grupo Aeroportuario del Centro Norte, S.

A. B. de C. V. (OMAB) is the cheapest at 16. 7x versus argenx SE at 40. 1x. On forward P/E, Grupo Aeroportuario del Centro Norte, S. A. B. de C. V. is actually cheaper at 0. 8x.

Over the past 5 years, argenx SE (ARGX) delivered a total return of +198.

6%, compared to -77. 2% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: ARGX returned +33. 2% versus IFRX's -82. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), argenx SE (ARGX) is the lower-risk stock at 0.

52β versus InflaRx N. V. 's 2. 08β — meaning IFRX is approximately 296% more volatile than ARGX relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 119% for Grupo Aeroportuario del Centro Norte, S. A. B. de C. V. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), argenx SE (ARGX) is pulling ahead at 90.

1% versus -83. 0% for InflaRx N. V. (IFRX). On earnings-per-share growth, the picture is similar: argenx SE grew EPS 53. 6% year-over-year, compared to -45. 2% for Immunovant, Inc.. Over a 3-year CAGR, ARGX leads at 116. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Grupo Aeroportuario del Centro Norte, S.

A. B. de C. V. (OMAB) is the more profitable company, earning 33. 5% net margin versus -1555. 8% for InflaRx N. V. — meaning it keeps 33. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OMAB leads at 56. 0% versus -1735. 9% for IFRX. At the gross margin level — before operating expenses — ARGX leads at 89. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Grupo Aeroportuario del Centro Norte, S.

A. B. de C. V. (OMAB) trades at 0. 8x forward P/E versus 30. 0x for argenx SE — 29. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RARE: 97. 1% to $51. 50.

In this comparison, OMAB (5.

0% yield) pays a dividend. IFRX, ARGX, RARE, IMVT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Grupo Aeroportuario del Centro Norte, S.

A. B. de C. V. (OMAB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 62), 5. 0% yield, +192. 8% 10Y return). InflaRx N. V. (IFRX) carries a higher beta of 2. 08 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (OMAB: +192. 8%, IFRX: -82. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (IFRX (Healthcare) and ARGX (Healthcare) and OMAB (Industrials) and RARE (Healthcare) and IMVT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: IFRX is a small-cap quality compounder stock; ARGX is a mid-cap high-growth stock; OMAB is a small-cap deep-value stock; RARE is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock. OMAB pays a dividend while IFRX, ARGX, RARE, IMVT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.